Oncology Pipeline Agents

MEDICAL INQUIRIES

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Find Your Medical Representative

Find your Medical Representative based on your therapeutic area and zip code.

THERAPEUTIC AREAS

Therapeutic Areas

Therapeutic Areas

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

DISEASE AWARENESS

Disease Awareness

Disease Awareness

Disease Awareness

Find information on disease areas of interest

Marketed Products

Marketed Products

Find information on our marketed products

Pipeline Agents

Pipeline Agents

Find information on our pipeline agents

CONGRESSES AND PUBLICATIONS

Congress Presentations

Congress Presentations

Explore our library of congress presentations

Journal Publications

Journal Publications

Discover our library of select journal publications

FIND YOUR MEDICAL REPRESENTATIVE Accredited Continuing Education Patient Resources Patient and Caregiver Medical Website

eMedI Chat

eMedI Chat

ONCOLOGY PIPELINE AGENTS

Please note that this page may contain information on EMD Serono marketed and/or investigational products. Investigational agents and investigational indications for marketed products are under clinical investigation and have not been proven to be safe and effective. There is no guarantee that any product will be approved in the sought-after indication. Please click here to view the full EMD Serono pipeline.

Oncogenic Signaling Antibody Drug Conjugates DNA Damage Response Immuno-oncology

Oncogenic Signaling

Learn more about tenosynovial giant cell tumor disease mechanism

Pimicotinib (ABSK021) is an oral, small-molecule inhibitor of colony-stimulating factor-1 receptor (CSF-1R) that is under clinical investigation in patients with tenosynovial giant cell tumor (TGCT). Pimicotinib is being developed by Abbisko Therapeutics Co. Ltd., Shanghai, China. Merck KGaA, Darmstadt, Germany holds the rights to commercialize pimicotinib worldwide.

Learn more about all pimicotinib (ABSK021) clinical trials at clinicaltrials.gov

Antibody Drug Conjugates (ADCs)

Learn more about ADC technology

Precemtabart tocentecan (M9140) is an anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) ADC designed to deliver the TOP1-inhibitor exatecan to CEACAM5-overexpressing tumor cells that is under clinical investigation in patients with advanced colorectal cancer (CRC) and other solid tumors.

Phase 1 study in patients with advanced CRC: click here to see the PROCEADE-CRC-01 study design

Phase 1b/2 study in patients with advanced solid tumors (gastric cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma): click here to see the PROCEADE-PanTumor study design

Learn more about all precemtabart tocentecan (M9140) clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting precemtabart tocentecan (M9140) clinical trials

M3554 is an anti-GD2 ADC with a unique linker-payload combination to selectively deliver the TOP1-inhibitor exatecan to GD2 overexpressing tumor cells that is under clinical investigation in patients with soft tissue sarcoma and glioblastoma.

Phase 1 study in patients with soft tissue sarcoma and glioblastoma: click here to see the study design

Learn more about all M3554 clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting M3554 clinical trials

DNA Damage Response (DDR)

Learn more about DDR

Tuvusertib is an ATR (ataxia telangiectasia and Rad3 related kinase) inhibitor under clinical investigation in patients with advanced solid tumors, including epithelial ovarian cancer and prostate cancer.

Phase 2 study in patients with epithelial ovarian cancer (tuvusertib in combination with lartesertib or niraparib): click here to see the DDRiver 302 study design

Phase 1 study in patients with advanced solid tumors (tuvusertib in combination with niraparib): click here to see the DDRiver 301 study design

Phase 1 study in patients with advanced solid tumors (tuvusertib in combination with lartesertib or avelumab): click here to see the DDRiver 320 study design

Phase 1 study in patients with advanced solid tumors, including prostate cancer (M9466 alone or in combination with tuvusertib or abiraterone acetate and prednisone): click here to see the DDRiver 501 study design

Learn more about all tuvusertib clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting tuvusertib clinical trials

Lartesertib is an ATM (ataxia telangiectasia mutated kinase) inhibitor under clinical investigation in patients with advanced solid tumors, including ovarian cancer.

Phase 2 study in patients with epithelial ovarian cancer (tuvusertib in combination with lartesertib or niraparib): click here to see the DDRiver 302 study design

Phase 1 study in patients with advanced solid tumors (tuvusertib in combination with lartesertib or avelumab): click here to see the DDRiver 320 study design

Learn more about all lartesertib clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting lartesertib clinical trials

M9466 is a PARP1 (poly (ADP-ribose) polymerase 1) inhibitor under clinical investigation in patients with advanced solid tumors, including prostate cancer, colorectal cancer, and small-cell lung cancer.

The Healthcare business of Merck KGaA, Darmstadt, Germany obtained exclusive rights from Jiangsu Hengrui Pharmaceuticals Co., Ltd. to develop, manufacture, and commercialize M9466 (also known as HRS-1167) outside China.

Phase 1 study in patients with advanced solid tumors, including prostate cancer (M9466 alone or in combination with tuvusertib or abiraterone acetate and prednisone): click here to see the DDRiver 501 study design

Phase 1 study in patients with advanced solid tumors, including colorectal cancer (M9466 in combination with FOLFIRI and bevacizumab): click here to see the DDRiver 511 study design

Phase 1 study in patients with advanced solid tumors, including small cell lung cancer (M9466 in combination with carboplatin, etoposide, and atezolizumab): click here to see the DDRiver 521 study design

Learn more about all M9466 clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting M9466 clinical trials

Immuno-oncology

Avelumab is an anti-PD-L1 antibody under clinical investigation in patients with solid tumors.

Phase 2 study in patients with locally advanced or metastatic urothelial carcinoma (avelumab alone or in combination with sacituzumab govitecan, M6223, or NKTR-255 as a maintenance treatment): click here to see the JAVELIN Bladder Medley study design

Learn more about all avelumab clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting avelumab clinical trials

M6223 is an anti-TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains) antibody under clinical investigation in patients with solid tumors.

Phase 2 study in patients with locally advanced or metastatic urothelial carcinoma (avelumab alone or in combination with sacituzumab govitecan, M6223, or NKTR-255 as a maintenance treatment): click here to see the JAVELIN Bladder Medley study design

Learn more about all M6223 clinical trials at clinicaltrials.gov

Click here to find participating sites for currently recruiting M6223 clinical trials

Patient Resources

EMD Serono Clinical Trials

Research

Investigator Sponsored Studies (ISSs) and Medical Education Grants (MEGs)

Additional Oncology Resources

US-NONO-00760 04/25

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 04/25

© 2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options: